Clinical predictors for survival with the addition of chemotherapy in patients with recurrent-metastatic squamous cell carcinoma of the head and neck after progression on immune checkpoint inhibitors

被引：1
|
作者：
Issa, M. [1 ]
Klamer, B. [2 ]
Bhateja, P. [3 ]
Karivedu, V. [3 ]
Laliotis, G. [4 ]
Dibs, K. [5 ]
Mladkova, N. [5 ]
Pan, X.
Old, M. [5 ]
Gamez, M. [5 ]
Grecula, J. [5 ]
Jhawar, S. [5 ]
Mitchell, D. [5 ]
Baliga, S. [5 ]
Carrau, R. [6 ]
Rocco, J. [6 ]
Bonomi, M. [3 ]
Blakaj, D.
机构：
[1] Ohio State Univ, Med Oncol, James Canc Hosp, Columbus, OH USA
[2] Ohio State Univ, Sch Biomed Sci, Ctr Biostat, OSUCCC,Comprehens Canc Ctr, Columbus, OH USA
[3] Ohio State Univ, Dept Med Oncol, OSUCCC, Comprehens Canc Ctr, Columbus, OH USA
[4] Sidney Kimmel Comprehensive Canc Ctr, Med Oncol, Baltimore, MD USA
[5] Ohio State Univ, Radiat Oncol, Comprehens Canc Ctr, OSUCCC, Columbus, OH USA
[6] Ohio State Univ, Otolaryngol, James Canc Hosp, Columbus, OH USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1298
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
888P
引用
收藏
页码：S797 / S798
页数：2
相关论文
共 50 条
  • [1] Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Saleh, Khalil
    Daste, Amaury
    Martin, Nicolas
    Pons-Tostivint, Elvire
    Auperin, Anne
    Herrera-Gomez, Ruth Gabriela
    Baste-Rotllan, Neus
    Bidault, Francois
    Guigay, Joel
    Le Tourneau, Christophe
    Saada-Bouzid, Esma
    Even, Caroline
    EUROPEAN JOURNAL OF CANCER, 2019, 121 : 123 - 129
  • [2] Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck
    Kacew, Alec J.
    Harris, Ethan J.
    Lorch, Jochen H.
    Schoenfeld, Jonathan D.
    Margalit, Danielle N.
    Kass, Jason, I
    Tishler, Roy B.
    Haddad, Robert, I
    Hanna, Glenn J.
    ORAL ONCOLOGY, 2020, 105
  • [3] Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Suzuki, Shinsuke
    Toyoma, Satoshi
    Kawasaki, Yohei
    Koizumi, Koh
    Iikawa, Nobuko
    Shiina, Kazuhiro
    Endo, Tentaro
    Abe, Tomoe
    Kouga, Teppei
    Yamada, Takechiyo
    MEDICINA-LITHUANIA, 2021, 57 (11):
  • [4] Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression on immune checkpoint inhibitors.
    Issa, Majd
    Klamer, Brett
    Karivedu, Vidhya
    Bhateja, Priyanka
    Laliotis, Georgios I.
    Dibs, Khaled
    Mladkova, Nikol
    Pan, Xueliang Jeff
    Old, Matthew O.
    Gamez, Mauricio
    Grecula, John C.
    Jhawar, Sachin R.
    Mitchell, Darrion L.
    Baliga, Sujith
    Carrau, Ricardo
    Rocco, James William
    Blakaj, Dukagjin
    Bonomi, Marcelo Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.
    Saleh, Khalil
    Daste, Amaury
    Martin, Nicolas
    Pons-Tostivint, Elvire
    Auperin, Anne
    Herrera-Gomez, Ruth Gabriela
    Baste, Neus
    Bidault, Francois
    Guigay, Joel
    Le Tourneau, Christophe
    Saada, Esma
    Even, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors
    Sakai, Akihiro
    Ebisumoto, Koji
    Iijima, Hiroaki
    Yamauchi, Mayu
    Teramura, Takanobu
    Yamazaki, Aritomo
    Watanabe, Takane
    Inagi, Toshihide
    Maki, Daisuke
    Okami, Kenji
    DISCOVER ONCOLOGY, 2023, 14 (01)
  • [7] Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors
    Akihiro Sakai
    Koji Ebisumoto
    Hiroaki Iijima
    Mayu Yamauchi
    Takanobu Teramura
    Aritomo Yamazaki
    Takane Watanabe
    Toshihide Inagi
    Daisuke Maki
    Kenji Okami
    Discover Oncology, 14
  • [8] Salvage chemotherapy after progression on immunotherapy in recurrent/metastatic squamous cell head and neck carcinoma
    Llop, Sandra
    Plana, Maria
    Tous, Sara
    Ferrando-Diez, Angelica
    Brenes, Jesus
    Juarez, Marc
    Vidales, Zara
    Vilajosana, Esther
    Linares, Isabel
    Arribas, Lorena
    Duch, Maria
    Fulla, Marta
    Brunet, Aina
    Lozano, Alicia
    Cirauqui, Beatriz
    Mesia, Ricard
    Oliva, Marc
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [9] A nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
    Mousa, L.
    Issa, M.
    Klamer, B.
    Pan, J.
    Old, M.
    Kang, S.
    Agrawal, A.
    Ozer, E.
    Carrau, R.
    Bhateja, P.
    Rupert, R.
    Jhawar, S.
    Mitchell, D.
    Gamez, M.
    Rocco, J.
    Blakaj, D.
    Bonomi, M. R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Taxanes plus cetuximab with or without platinum chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.
    Saleh, Khalil
    Vinches, Marie
    Safta, Inga
    Guiard, Emeline
    Marret, Gregoire
    Vion, Roman
    Guigay, Joel
    Ferrand, Francois-Regis
    Clatot, Florian
    Le Tourneau, Christophe
    Rambeau, Audrey
    Saada-Bouzid, Esma
    Daste, Amaury
    Even, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345